Difference between revisions of "Colorectal cancer, KRAS-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - ":Section editor transclusions|" to ":Editorial board transclusions|") |
m |
||
| Line 12: | Line 12: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| + | =Guidelines= | ||
| + | ==[https://www.nccn.org/ NCCN]== | ||
| + | *''NCCN does not have guidelines at this granular level; please see [https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf NCCN Guidelines - Colon Cancer].'' | ||
=Advanced or metastatic disease, subsequent lines of therapy= | =Advanced or metastatic disease, subsequent lines of therapy= | ||
==Adagrasib monotherapy {{#subobject:fgac16|Regimen=1}}== | ==Adagrasib monotherapy {{#subobject:fgac16|Regimen=1}}== | ||
Revision as of 16:39, 4 September 2023
| Section editor | |
|---|---|
 |
Travis Zack, MD, PhD University of California San Francisco San Francisco, CA, USA |
Note: the page has regimens specific to BRAF-mutated colon cancer.
- See the main colorectal cancer page for general regimens.
5 regimens on this page
8 variants on this page
|
Guidelines
NCCN
- NCCN does not have guidelines at this granular level; please see NCCN Guidelines - Colon Cancer.
Advanced or metastatic disease, subsequent lines of therapy
Adagrasib monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Yaeger et al. 2022 (KRYSTAL-1) | NR in abstract | Phase 1/2 |
Biomarker eligibility criteria
- KRAS p.G12C mutation
References
- KRYSTAL-1: Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, Leal TA, Bekaii-Saab TS, Paweletz CP, Heavey GA, Christensen JG, Velastegui K, Kheoh T, Der-Torossian H, Klempner SJ. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023 Jan 5;388(1):44-54. Epub 2022 Dec 21. link to original article contains dosing details in abstract link to PMC article PubMed NCT03785249
Adagrasib & Cetuximab
Regimen variant #1
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Yaeger et al. 2022 (KRYSTAL-1) | NR in abstract | Phase 1/2 |
Biomarker eligibility criteria
- KRAS p.G12C mutation
Targeted therapy
- Adagrasib (Krazati) 600 mg PO twice per day
- Cetuximab (Erbitux) as follows:
- Cycle 1: 400 mg IV once on day 1
- Cycle 2 onwards: 250 mg IV once on day 1
7-day cycles
Regimen variant #2
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Yaeger et al. 2022 (KRYSTAL-1) | NR in abstract | Phase 1/2 |
Biomarker eligibility criteria
- KRAS p.G12C mutation
Targeted therapy
- Adagrasib (Krazati) 600 mg PO twice per day
- Cetuximab (Erbitux) 500 mg IV once on day 1
14-day cycles
References
- KRYSTAL-1: Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, Leal TA, Bekaii-Saab TS, Paweletz CP, Heavey GA, Christensen JG, Velastegui K, Kheoh T, Der-Torossian H, Klempner SJ. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023 Jan 5;388(1):44-54. Epub 2022 Dec 21. link to original article contains dosing details in abstract link to PMC article PubMed NCT03785249